Literature DB >> 31442642

Preoperative Neutrophil/Lymphocyte Ratio Is an Independent Prognostic Biomarker in Patients with Low-Grade Gliomas.

Zhaohua Tan1, Liangfang Shen1, Haijun Wu1, Liang Deng1, Zhanzhan Li1, Xinqiong Huang2.   

Abstract

BACKGROUND: There are no standardized criteria to predict the prognosis of patients with low-grade gliomas. Therefore, novel prognostic biomarkers that can guide follow-up schedules and therapeutic approaches urgently are required in patients with low-grade gliomas.
METHODS: One hundred nineteen patients with World Health Organization (WHO) II gliomas were recruited between January 2010 and December 2016 from Xiangya Hospital for this study. We collected neutrophil and lymphocyte values from the full blood counts measured 24 h before surgery. Neutrophil-to-lymphocyte ratios (NLRs) were then calculated. The significance of the NLR was determined based on a nonparametric test. The Kaplan-Meier method was used to estimate survival rates. The influence of the NLR on progression-free survival and overall survival was evaluated using univariate and multivariate Cox proportional hazards models.
RESULTS: Preoperative NLRs were upregulated in patients with WHO II gliomas who relapsed or died. Preoperative NLRs were also significantly correlated with age, preoperative neutrophil values, and preoperative lymphocyte values. Compared with the low preoperative NLR group, patients with WHO II gliomas in the high preoperative NLR group had significantly higher relapse and lower survival rates. In addition, the preoperative NLR and tumor type were independent prognostic parameters of progression-free survival for WHO II gliomas, whereas only the preoperative NLR was an independent prognostic parameter of overall survival for WHO II gliomas.
CONCLUSIONS: High preoperative NLRs were significantly associated with greater relapse and poor prognosis in patients with WHO II gliomas.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glioma; Low-grade; Lymphocyte; Neutrophil; Ratio

Mesh:

Substances:

Year:  2019        PMID: 31442642     DOI: 10.1016/j.wneu.2019.08.068

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  3 in total

1.  Commentary: Evaluating potential glioma serum biomarkers, with future applications.

Authors:  Michael Goutnik; Brandon Lucke-Wold
Journal:  World J Clin Oncol       Date:  2022-05-24

2.  A prospective study of inflammatory biomarkers and growth factors and risk of glioma in the UK Biobank.

Authors:  David J Cote; Jordan H Creed; Claudine M Samanic; Travis A Gerke; Meir J Stampfer; Stephanie A Smith-Warner; Kathleen M Egan
Journal:  Cancer Epidemiol       Date:  2021-09-24       Impact factor: 2.984

3.  Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.

Authors:  Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.